OBI.LSE Ondine Biomedical Inc

Healthcare Biotechnology London Exchange
0.0950 GBX
Close of Nov 3, 2026
7.50 15.50
Market cap
GBX 62.8M
P/E
-
P/B
27.31x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is OBI.LSE undervalued?

Graham number

The Graham number of Ondine Biomedical Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ondine Biomedical Inc fundamental analysis

No fundamental analysis for Ondine Biomedical Inc yet.

Ondine Biomedical Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ondine Biomedical Inc

Ondine Biomedical Inc., a life-sciences company, engages in the development of activated antimicrobial therapies for the prevention and treatment of infections in Canada and internationally. Its primary product is Steriwave, a non-invasive, nurse-administered treatment that eliminates harmful bacteria, viruses, and fungi from the nose. In addition, the company offers a pipeline of photodisinfection products for various indications, including chronic sinusitis, ventilator-ass…

Full company profile